- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03671798
Establish a National Registry of REM Sleep Behavior Disorder
August 5, 2021 updated by: Dr. Zhang Jihui, Chinese University of Hong Kong
Establish a National Registry to Search for the Risk Factors, Etiology, and Neurodegenerative Progression of REM Sleep Behavior Disorder
In this proposed study, the investigators aim to build up a large cohort of Rapid eye movement sleep behavior disorder (RBD) to study the etiology and risk factors of neurodegeneration.
Study Overview
Status
Recruiting
Conditions
Detailed Description
REM sleep behavior disorder (RBD) is a parasomnia characterized by abnormal behavioral manifestations during REM sleep.
Accumulating evidence suggests that RBD is implicated as an integral part of disease progress of α-synucleinopathy neurodegeneration, such as Parkinson's disease (PD) and dementia with Lewy bodies.Previous studies have identified a series of neurocognitive, autonomic, clinical and neurobiological markers for neurodegeneration in iRBD, such as olfactory dysfunction, color vision deficit, autonomic dysfunction, tonic EMG activity during REM sleep, and psychiatric disorder.
However, the prevalence rate of RBD was relatively low and most of the RBD studies only have 100 or below cases.
and there might be ethic differences in RBD which indicates that the findings from western countries might not be applicable to Chinese.
In these regards, the investigators aimed to build up a large cohort of Rapid eye movement sleep behavior disorder (RBD) to study the etiology and risk factors of neurodegeneration.
Study Type
Observational
Enrollment (Anticipated)
3000
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Jihui Zhang, PhD
- Phone Number: (852) 39197647
- Email: jihui.zhang@cuhk.edu.hk
Study Locations
-
-
-
Hong Kong, Hong Kong
- Recruiting
- Department of psychiatry, Faculty of Medicine, The Chinese University of Hong Kong
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Non-Probability Sample
Study Population
Subjects will be recruited from psychiatry outpatient clinics, Prince of Wales Hospital and 11 collaborated sites in mainland China.
Description
Inclusion Criteria:
Case: According to the ICSD-3 for the diagnosis of RBD
- Sleep talking or complex movement during sleep;
- Such movement was recorded by video PSG (AV-PSG) during REM sleep or according to history the movements were occurred during REM;
- REM sleep without atonia (RWA) during PSG monitoring;
- This abnormal phenomenon cannot be explained by other sleep disorder, psychiatric disease, drug or substance abuse.
Control: Age and gender matched with consent
- No RBD symptoms and PSG characteristics;
- No neurological symptoms or diseases, MRI scan will be employed to exclude brain pathology;
- No narcolepsy or hypersomnia, ruled out by multiple sleep latency test;
- No history of mental illnesses or use of antidepressants.
Exclusion Criteria:
1. Subjects who refused to join the cohort.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Observational Models: Case-Control
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
|---|
|
REM sleep behavior disorder (RBD)
Diagnosis of RBD according to ICSD-3: 1) Sleep talking or complex movement during sleep.
2) Such movement was recorded by video PSG (AV-PSG) during REM sleep or according to history the movements were occurred during REM. 3) REM sleep without atonia (RWA) during PSG monitoring.
4) This abnormal phenomenon cannot be explained by other sleep disorder, psychiatric disease, drug or substance abuse.
|
|
Controls
Subjects with 1) No RBD symptoms and PSG characteristics.
2) No neurological symptoms or diseases, MRI scan will be employed to exclude brain pathology.
3) No narcolepsy or hypersomnia, ruled out by multiple sleep latency test.
4) No history of mental illnesses or use of antidepressants
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Risk factors for neurodegenerative diseases in rapid eye movement sleep behavior disorder.
Time Frame: 1 hour
|
Risk factors for neurodegenerative diseases were investigated in rapid eye movement sleep behavior disorder by questionnaires, including general information, life history, occupational history and family history.
|
1 hour
|
|
Changes of neurocognitive biomarkers for neurodegenerative diseases in rapid eye movement sleep behavior disorder.
Time Frame: Baseline and biennial follow-up, up to 20 years
|
Based on the large cohort of RBD, the investigators aim to study the etiology and the progression of neurocognitive biomarkers for neurodegenerative diseases in rapid eye movement sleep behavior disorder by clinical assessment, including MoCA, olfactory dysfunction, color vision deficit and so on.
|
Baseline and biennial follow-up, up to 20 years
|
|
Changes of autonomic dysfunctions for neurodegenerative diseases in rapid eye movement sleep behavior disorder.
Time Frame: Baseline and biennial follow-up, up to 20 years
|
Autonomic dysfunctions are also biomarkers for neurodegenerative diseases, the investigators aim to observe the changes of autonomic dysfunctions, including constipation, orthostatic hypotension and so on.
|
Baseline and biennial follow-up, up to 20 years
|
|
Changes of REM-related EMG activity (REMREEA) and motor activity in rapid eye movement sleep behavior disorder.
Time Frame: Baseline and biennial follow-up, up to 20 years
|
The percentage of REM-related EMG activity (REMREEA) is the most reliable and valid marker in differentiating patients with RBD from normal controls.
Both REMREEA and significant motor activity were recorded by video-polysomnography in rapid eye movement sleep behavior disorder.
|
Baseline and biennial follow-up, up to 20 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
October 1, 2014
Primary Completion (Anticipated)
April 1, 2022
Study Completion (Anticipated)
April 1, 2022
Study Registration Dates
First Submitted
August 30, 2018
First Submitted That Met QC Criteria
September 12, 2018
First Posted (Actual)
September 14, 2018
Study Record Updates
Last Update Posted (Actual)
August 6, 2021
Last Update Submitted That Met QC Criteria
August 5, 2021
Last Verified
August 1, 2021
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2014.445
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Undecided
IPD Plan Description
Researcher in other sleep centers are also conducting similar study, there may be a plan for further collaboration on sharing the database
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on REM Sleep Behavior Disorder
-
University of ManitobaRecruitingSleepwalking | Sleep Terror | Nightmare Disorder | REM Sleep Behavior Disorder (iRBD) | Confusional ArousalCanada
-
Brigham and Women's HospitalVanda PharmaceuticalsTerminatedREM Behavior DisorderUnited States
-
Universita di VeronaRecruitingREM Sleep Behavior Disorder | Isolated REM Sleep Behavior DisorderItaly
-
CND Life SciencesActive, not recruiting
-
University Hospital, ToulouseRecruitingNarcolepsy Type 1 | REM Sleep Behavior Disorder (iRBD)France
-
The University of Texas Health Science Center,...Active, not recruitingRapid Eye Movement Sleep Behavior DisorderUnited States
-
SyntaraActive, not recruitingREM Sleep Behavior DisorderAustralia, United Kingdom
-
Beijing Hospital of Traditional Chinese MedicineNot yet recruitingRapid Eye Movement Sleep Behavior Disorder
-
Chinese University of Hong KongRecruitingREM Sleep Behavior DisorderHong Kong